WO2013160474A3 - Expression de miarn dans les maladies hématologiques - Google Patents

Expression de miarn dans les maladies hématologiques Download PDF

Info

Publication number
WO2013160474A3
WO2013160474A3 PCT/EP2013/058811 EP2013058811W WO2013160474A3 WO 2013160474 A3 WO2013160474 A3 WO 2013160474A3 EP 2013058811 W EP2013058811 W EP 2013058811W WO 2013160474 A3 WO2013160474 A3 WO 2013160474A3
Authority
WO
WIPO (PCT)
Prior art keywords
mirnas
mds
signature
print
finger
Prior art date
Application number
PCT/EP2013/058811
Other languages
English (en)
Other versions
WO2013160474A2 (fr
Inventor
Pilar Giraldo Castellano
Marta ANDRÉS CORDURAS
Miguel Pocovi Mieras
Original Assignee
Instituto Aragonés De Ciencias De La Salud
Universidad De Zaragoza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Aragonés De Ciencias De La Salud, Universidad De Zaragoza filed Critical Instituto Aragonés De Ciencias De La Salud
Publication of WO2013160474A2 publication Critical patent/WO2013160474A2/fr
Publication of WO2013160474A3 publication Critical patent/WO2013160474A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

Les microARN (miARN) sont une classe de petits ARN endogènes qui sont des régulateurs négatifs de l'expression des gènes. Les miARN interviennent dans différents processus biologiques y compris l'hématopoïèse, laissant penser qu'ils sont associés au cancer. La présente invention concerne une signature/empreinte de miARN, exprimés différentiellement chez les sujets atteints de MDS relativement aux témoins sains, pour le diagnostic et le pronostic de MDS. De plus, la signature/empreinte des miARN décrite dans la présente invention est associée à des sous-types spécifiques de MDS, permettant l'identification du stade ou de la progression de la maladie, et elle pourrait être utilisée pour mettre au point une réponse thérapeutique adéquate chez différents patients.
PCT/EP2013/058811 2012-04-26 2013-04-26 Expression de miarn dans les maladies hématologiques WO2013160474A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261638837P 2012-04-26 2012-04-26
US61/638,837 2012-04-26

Publications (2)

Publication Number Publication Date
WO2013160474A2 WO2013160474A2 (fr) 2013-10-31
WO2013160474A3 true WO2013160474A3 (fr) 2014-01-03

Family

ID=48444348

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/058811 WO2013160474A2 (fr) 2012-04-26 2013-04-26 Expression de miarn dans les maladies hématologiques

Country Status (1)

Country Link
WO (1) WO2013160474A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036776A2 (fr) * 2006-09-19 2008-03-27 Asuragen, Inc. Gènes régulés mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p et voies de signalisation utiles comme cibles dans une intervention thérapeutique
WO2008088858A2 (fr) * 2007-01-17 2008-07-24 The Johns Hopkins University Compositions et procédés comprenant des microarn pour traiter une néoplasie
WO2009140670A2 (fr) * 2008-05-16 2009-11-19 Veridex, Llc Procédé d'évaluation du cancer colorectal et compositions utilisables à cet effet
WO2011094683A2 (fr) * 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Méthode d'identification des syndromes myélodysplasiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036776A2 (fr) * 2006-09-19 2008-03-27 Asuragen, Inc. Gènes régulés mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p et voies de signalisation utiles comme cibles dans une intervention thérapeutique
WO2008088858A2 (fr) * 2007-01-17 2008-07-24 The Johns Hopkins University Compositions et procédés comprenant des microarn pour traiter une néoplasie
WO2009140670A2 (fr) * 2008-05-16 2009-11-19 Veridex, Llc Procédé d'évaluation du cancer colorectal et compositions utilisables à cet effet
WO2011094683A2 (fr) * 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Méthode d'identification des syndromes myélodysplasiques

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEGUM ERDOGAN ET AL: "Diagnostic microRNAs in myelodysplastic syndrome", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 39, no. 9, 2 June 2011 (2011-06-02), pages 915 - 926.e2, XP028264565, ISSN: 0301-472X, [retrieved on 20110615], DOI: 10.1016/J.EXPHEM.2011.06.002 *
LUBOMIR SOKOL ET AL: "Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes", BRITISH JOURNAL OF HAEMATOLOGY, vol. 153, no. 1, 1 April 2011 (2011-04-01), pages 24 - 32, XP055045349, ISSN: 0007-1048, DOI: 10.1111/j.1365-2141.2011.08581.x *
PONS AINA ET AL: "Hematopoiesis-related microRNA expression in myelodysplastic syndromes.", LEUKEMIA & LYMPHOMA NOV 2009, vol. 50, no. 11, November 2009 (2009-11-01), pages 1854 - 1859, XP008163986, ISSN: 1029-2403 *
WANG Y ET AL: "MicroRNAs expression signatures are associated with lineage and survival in acute leukemias", BLOOD CELLS, MOLECULES AND DISEASES, LAJOLLA, US, vol. 44, no. 3, 15 March 2010 (2010-03-15), pages 191 - 197, XP026919905, ISSN: 1079-9796, [retrieved on 20100127], DOI: 10.1016/J.BCMD.2009.12.010 *
Z. ZUO ET AL: "Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome", BLOOD, vol. 118, no. 2, 14 July 2011 (2011-07-14), pages 413 - 415, XP055074297, ISSN: 0006-4971, DOI: 10.1182/blood-2011-01-330704 *

Also Published As

Publication number Publication date
WO2013160474A2 (fr) 2013-10-31

Similar Documents

Publication Publication Date Title
WO2013066764A3 (fr) Marqueurs de signature de la maladie d'alzheimer et procédés d'utilisation
EP3236262A3 (fr) Essai de diagnostic fonctionnel de substitut pour le cancer
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
WO2013182912A3 (fr) Méthode pour le diagnostic, le pronostic et le traitement d'une métastase du cancer du poumon
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
WO2012038068A3 (fr) Moyens et procédés pour la prévision de la réponse à un traitement d'un patient cancéreux
BR112013010023A2 (pt) algoritimo aperfeiçoado para a detecção de diabetes
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
WO2014179765A3 (fr) Nouveaux miarn humains à utiliser dans le diagnostic, le pronostic et la thérapie de maladies et d'états humains
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
CY1120084T1 (el) Oλiγονουκλεοτiδiα για τη ρυθμιση της γονιδιακης εκφρασης και οι χρησεις αυτων
WO2014060848A3 (fr) Procédés de traitement utilisant un adénovirus
EP2414549A4 (fr) Micro-arn d'expression différentielle utilisés comme biomarqueurs du diagnostic du syndrome de sjögren et traitement associé
WO2011112903A3 (fr) Détection par rt-pcr quantitative de gènes impliqués dans la transition épithélio-mésenchymateuse dans le sang périphérique de patients souffrant du cancer de sein
WO2014057357A3 (fr) Méthode pour le diagnostic, le pronostic et le traitement d'une métastase du cancer de la prostate
BR112014003877A2 (pt) biomarcadores de micro-rna e métodos de uso dos mesmos
EP3495502A3 (fr) Biomarqueurs pour la naissance prématurée
WO2012109233A3 (fr) Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein
WO2012101219A3 (fr) Ensembles de miarn complexes en tant que nouveaux biomarqueurs pour des maladies pulmonaires
WO2013124740A3 (fr) Dysfonctionnement de la protéine brca et signatures arnm utiles dans l'identification de patients atteints de tumeurs dues au dysfonctionnement de la protéine brca et prévision des bénéfices d'une thérapie anti-cancer sur des patients atteints de cancer
BR112015028997A2 (pt) biomarcadores de expressão gênica e seu uso para a aplicação diagnóstica e prognóstica em pacientes potencialmente com necessidade de tratamento de inibidor de hdac
WO2013160474A3 (fr) Expression de miarn dans les maladies hématologiques
EA201490201A1 (ru) Выявление экспрессии гена prame при раковом заболевании
WO2014153442A3 (fr) Procédés et systèmes pour le traitement du cancer des ovaires
EA201501095A1 (ru) Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13722715

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13722715

Country of ref document: EP

Kind code of ref document: A2